BTS is set to transform NYC with immersive experiences, expanding their The City project after successful events in Seoul, Busan, and London.

When Volkswagen announced its plan to invest...

Celltrion has launched Omlyclo, the first omalizumab biosimilar in the U.S., for chronic spontaneous urticaria and allergic asthma, with preferred formulary placement from major pharmacy benefit manager Optum.